SHORT MINI FUTURE WARRANT - BRISTOL-MYERS SQUIBB | Real-time BOERSE MUENCHEN 14:26:40 2024-06-07 EDT | ||
| 2.201 EUR | -0.14% |
|
| 1 month | +13.61% | ||
| 3 months | +97.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 2.201 | -0.14% |
| 24-06-06 | 2.204 | +0.78% |
| 24-06-05 | 2.187 | +2.92% |
| 24-06-04 | 2.125 | +0.85% |
| 24-06-03 | 2.107 | -4.40% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 02:26 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Goldman Sachs |
| WKN | GQ00EE |
| ISIN | DE000GQ00EE2 |
| Date issued | 2023-07-25 |
| Strike | 64.95 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.304 € |
|---|---|
| Lowest since issue | 0.228 € |
| Spread | 0.01 € |
| Spread % | 0.46% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.88
USD
Average target price
53.19
USD
Spread / Average Target
+30.12%
- Stock Market
- Certificates
- Certificat
